Ioxaglate Sodium

CHEMBL1200743 Phase 4 Approved Small molecule
Half-Life
β€”
Bioavailability
β€”
Protein Binding
β€”
Molecular Weight
1290.9 g/mol
LogP
β€”
Phase
4

A sodium salt form of ioxaglate, sharing the same therapeutic uses.

Molecular Weight

1290.9000 g/mol

TPSA

197.00 Ų

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNC(=O)c1c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(=O)[O-])c(I)c(C(=O)NCCO)c2I)c(I)c(N(C)C(C)=O)c1I.[Na+]

InChI

InChI=1S/C24H21I6N5O8.Na/c1-7(37)35(3)20-17(29)10(21(39)31-2)13(25)11(18(20)30)23(41)33-6-8(38)34-19-15(27)9(22(40)32-4-5-36)14(26)12(16(19)28)24(42)43;/h36H,4-6H2,1-3H3,(H,31,39)(H,32,40)(H,33,41)(H,34,38)(H,42,43);/q;+1/p-1

Molecular Formula

C24H20I6N5NaO8

HBD / HBA

5 / 8

Rotatable Bonds

10

Heavy Atoms

44

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A sodium salt form of ioxaglate, sharing the same therapeutic uses.

Yes, Ioxaglate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

References & Data Sources

  • ChEMBL β€” European Bioinformatics Institute (EBI). CHEMBL1200743. Open-access bioactivity database.
  • PubChem β€” National Center for Biotechnology Information (NCBI). CID 23688359. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.